scholarly journals Management of Short Alveolar Bone with Implant Retained Splinted Crown

2019 ◽  
Vol 53 (6) ◽  
Author(s):  
Primanda Nur Rahmania ◽  
Bambang Agustono ◽  
Nike Hendrijantini ◽  
Muhammad Dimas Aditya Ari
Keyword(s):  
Bone Density ◽  
Maxillary Sinus ◽  
Alveolar Bone ◽  
Posterior Region ◽  
Implant Placement ◽  
Low Bone Density ◽  
History Of ◽  
Bone Height ◽  
Short Implant

Implant placement on maxillary posterior region has some limitations because of limited bone height, low bone density, and anatomical consideration involving the floor of the maxillary sinus. A 56-year-old male with a history of hypertension and stroke, consulted for edentulous in teeth 25 and 26 with limited bone height. A short implant for 26 (Ø 4.8 mm; 4 mm) and 25 (Ø 4.1 mm; 10 mm) were placed and splint crown was performed after 6 months.

scholarly journals Different Techniques For Sinus Floor Elevation: A Review Part II – Indirect Techniques

2021 ◽  
Vol 9 (1) ◽  
pp. 1-4
Author(s):  
Nitin Kothari ◽  
Vivek Jadhav ◽  
Snigdha Patil
Keyword(s):  
Minimally Invasive ◽  
Maxillary Sinus ◽  
Alveolar Bone ◽  
Effective Solution ◽  
Sinus Floor Elevation ◽  
Less Invasive ◽  
Implant Placement ◽  
Sinus Floor ◽  
Bone Height

The bone available for implant placement may be limited by the presence of the maxillary sinus togetherwith loss of alveolar bone height and it may be increased by augmentation. Minimally invasive sinusaugmentation is an effective solution for this problem. This review explains indirect sinus augmentationprocedures which are less invasive and highly successful if done using prescribed technique.

scholarly journals Comparison of 4 sinus augmentation techniques for implant placement with residual alveolar bone height ≤3 mm

Medicine ◽  
2020 ◽  
Vol 99 (46) ◽  
pp. e23180
Author(s):  
Chia-Fang Tsai ◽  
Whei-Lin Pan ◽  
Yi-Ping Pan ◽  
Chiu-Po Chan ◽  
Yuh-Ren Ju ◽  
...  
Keyword(s):  
Alveolar Bone ◽  
Sinus Augmentation ◽  
Implant Placement ◽  
Augmentation Techniques ◽  
Bone Height

scholarly journals Thin Alveolar Bone Height Can Cause Maxillary Sinus Mucosal Thickening:Computed Tomographic Study

2019 ◽  
Vol 18 (1) ◽  
pp. 22-26
Author(s):  
Iizuka Norihito ◽  
Kawashima Yusuke ◽  
Tokunaga Satoshi ◽  
Ito Kotaro ◽  
Hara Yoshinobu ◽  
...  
Keyword(s):  
Maxillary Sinus ◽  
Alveolar Bone ◽  
Bone Height

scholarly journals Premenopausal Osteoporosis & Perfluoroalkyl Substance Exposure; Is There a Link?

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A213-A213
Author(s):  
Bhavana Vemula ◽  
Omolola Bolaji Olajide
Keyword(s):  
Vitamin D ◽  
Lumbar Spine ◽  
Bone Density ◽  
Bone Mineralization ◽  
Consumer Products ◽  
Low Bone Density ◽  
Lower Lumbar Spine ◽  
Wide Range ◽  
Premenopausal Osteoporosis ◽  
History Of

Abstract Introduction: Perfluoroalkyl substances (PFAS) like Perflouroctanoate (PFOA) and Perflurooctane sulfonate (PFOS) are ubiquitous environmental contaminants that have been in industrial use for many years. Many known adverse effects include malignancies, reproductive and thyroid dysfunction. However, there is limited literature regarding PFAS causing low bone density. We report a case of a premenopausal woman with a history of exposure to PFAS who was recently diagnosed with osteoporosis. Clinical Case: A 36-year-old lady with a history of hypothyroidism, on levothyroxine, presented to the orthopedics clinic with complaints of sudden onset right foot pain with no trauma. She was found to have a fracture of her right second metatarsal bone. Notably, over a period of five years she had suffered multiple fractures including metatarsal, elbow and a wrist fracture, all with minimal or no trauma. She denied smoking, alcohol, chronic steroid or PPI use, history of malabsorption, celiac disease, kidney stones, malignancy or liver problems. Her menstrual cycles were regular; she was on oral contraceptives in the past for dysmenorrhea. She is on Vitamin D supplementation and consumes adequate dairy products daily. There is no family history of hip fracture or osteoporosis. Labs showed: Calcium 8.9mg/dl, Phosphorus 2.4mg/dl (2.5–4.5mg/dl), intact PTH was 92.7pg/ml (8-97pg/ml), 24-hour urine calcium was undetectable. Vitamin D was 56.6ng/ml (30-100ng/ml). CBC, TSH, FSH, liver & kidney functions were all normal. Anti-endomysial, anti-gliadin and anti-tissue trans glutaminase antibodies were all unremarkable. IgA level was 362mg/dl (8–352 mg/dl). DXA scan revealed the lowest Z-score (-3.1) in the lumbar spine. She reported a history of exposure to PFAS with a blood level of 22.3ng/ml for PFOA and 48.4ng/ml for PFOS in the year 2005. Plan is to initiate bisphosphonate therapy for the treatment of osteoporosis. Discussion: PFAS are known endocrine disruptive agents that have been used widely in making a wide range of consumer products including nonstick and stain-resistant coatings of cookware, food containers. Recent studies suggest that serum PFAS concentrations were associated with lower bone density. There was a higher incidence of lower lumbar spine bone density in patients exposed to PFOS. PFOA is believed to compete with calcitriol at the same binding site on Vitamin D receptor resulting in changes in the osteoblasts thereby decreasing bone mineralization. Conclusion: There needs to be increased awareness about the association of low bone density in patients exposed to PFAS. This is especially important in the evaluation of premenopausal osteoporosis. References: 1. Environ Health Perspect. 2016 Jan;124 (1):81–7, 2. J Clin Endocrinol Metab 2014; 99(6) 2173–2180, 3. Sci Rep 2020 Oct 8;1091):16789

scholarly journals Maxillary Sinus Floor Elevation

2018 ◽  
Vol 2 (2) ◽  
pp. 495-498
Author(s):  
Jorge Gatica ◽  
Claudio Garayar
Keyword(s):  
Maxillary Sinus ◽  
Oral Surgery ◽  
Sinus Lift ◽  
Sinus Floor Elevation ◽  
Rehabilitative Treatment ◽  
Implant Placement ◽  
Maxillary Sinus Floor ◽  
Sinus Floor ◽  
Bone Height ◽  
Maxillary Sinus Floor Elevation

The sinus lift is a procedure that is used frequently in oral surgery, different techniques exist to perform this procedure approaches, which allow the surgeon to give a sufficient bone height for planning a rehabilitative treatment with implant at the required site. In this case the unilateral lifting of the maxillary sinus floor by buccal bone window, with subsequent implant placement and lyophilized human bone in a single surgical procedure.

Low bone density in premenopausal women at high risk for breast cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1532-1532
Author(s):  
A. P. O'Dea ◽  
M. Thirunavu ◽  
J. Nydegger ◽  
J. R. Klemp ◽  
B. F. Kimler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Vitamin D ◽  
High Risk ◽  
Bone Density ◽  
Premenopausal Women ◽  
Sun Exposure ◽  
In Situ Carcinoma ◽  
Low Bone Density ◽  
History Of

1532 Background: Tamoxifen when used in the high estrogen milieu of premenopausal women may reduce bone density. However, the proportion of premenopausal women at increased risk for breast cancer who have low bone density and are likely to take tamoxifen is unknown. Methods: Premenopausal women attending a high-risk clinic were invited to take part in an ongoing prospective study assessing bone mineral density (BMD) loss. Women on bisphosphonates or those previously treated with selective estrogen receptor modulators were excluded. BMD was measured by DEXA, serum 25-hydroxyvitamin D (25OHD) by chemiluminescence, and information on risk factors for osteoporosis and breast cancer was obtained by questionnaire. Results: 106 premenopausal women were entered between April and October 2008. Median age was 42 (range 23–57), median body mass index (BMI) was 25 kg/m2 (range 15–44). All but two were Caucasian. 13% had a prior biopsy with atypical hyperplasia (AH) or in situ carcinoma, 36% had a family history of osteoporosis, 56% took calcium supplements, and 47% took vitamin D supplements. Median sun exposure was 480 minutes per month, the majority with sunscreen. Median serum 25OHD was 34 ng/ml. Five had deficiency (< 20 ng/mL), and 45 women deficiency or insufficiency (< 32 ng/mL). Seven subjects ages 31 to 48 had evidence of low BMD (T-score of less than -1.0 in the spine or hip.) One woman with low BMD by DEXA had a 25OHD level < 32 ng/ml. Women with low BMD had lower BMIs (median of 22 vs. 25 kg/m2, p = 0.020) than women with normal bone density. There was no difference in history of vitamin D and calcium supplement use, and low 25OHD levels did not explain the low T-scores. Information on vitamin D receptor polymorphisms associated with BMD loss is pending. Importantly, 21% of women with a prior biopsy demonstrating AH or in situ carcinoma had evidence of bone density loss compared to 4% of women without such a biopsy (p = 0.048). Conclusions: Premenopausal women with a history of AH or in situ carcinoma are most likely to take tamoxifen for primary prevention and in our ongoing study have a high enough incidence of low bone density to make baseline assessment by DEXA a consideration, particularly for those with predisposing factors such as low BMI and lack of sun exposure. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document